Management of Treatment-Experienced HIV-Infected Patients
Summary
- Ibalizumab-uiyk FDA approved in 2018 for use in combination with other ARV agents in heavily treatment–experienced patients with multidrug resistance who are experiencing failure of their current ART regimen
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content